Every so often, observers of the clinical research industry will publicly express concerns that physician practices, hospitals, and even CROs have a conflict of interest inherent to their business models because they are paid for research-related services.  The implication is that these entities could be motivated to make unethical decisions in order to protect their

Contract Research Organizations (CROs) have been around so long that you could forgive someone for assuming that their emergence was based on filling gaps in the expertise of sponsors.  But that is a relatively recent phenomenon that has only come about as the drug development industry has grown, forcing a higher degree of specialization and

So, a week removed from your last exhibit, that stack of business cards is still sitting on your desk.  Two of the cards have now shifted into a makeshift coaster for your afternoon latte.  Your exhibit ROI is slipping away faster than you can say, “venti double mocha”.  Not to worry, your follow up plan

Barry Mangum is a world-renowned expert in pediatric and neonatal pharmacology.  In addition to his faculty appointments at Duke University Medical Center, Dr. Mangum is Director of Clinical Pharmacology at Duke Clinical Research Unit.  He recently sat down with RxTi to share his insights on subject safety in Phase 1 clinical trials. ____________________________________________________________ The development

Some of my colleagues have attended the ACRP Global Conference for nearly twenty years.  A quick trip around the George R. Brown Convention Center explained why the meeting and Association has remained an important meeting for faithful attendees each year. We were greeted with a wave of smiles, handshakes, and even a few hugs from

Have you ever wondered what makes one exhibitor incredibly successful, while their neighbors flail and complain about poor traffic and poor results?  Each year, businesses everywhere plan to participate in a variety of conferences and tradeshows to demonstrate the uniqueness of their products and services, and in turn, accelerate the sales process. It seems impossible

Last week we gave helpful tips to sponsors and CROs that want their startup process to descend into mediocrity.  This week we turn our attention to sites, many of whom also do a fine job of delaying study startup – if you implement these same policies/procedures, we guarantee you will do your part to contribute

We have all read the research on why employees leave jobs.  Departures are typically due to some combination of dissatisfaction with a manager and lack of challenging assignments – and the two are often intertwined.  There are exceptions to this, of course, but workers ultimately want to feel valued – which often happens when their

Today’s article is a public service announcement to sponsors and CROs that feel their study startup processes are too fast and efficient.  If this describes you, and you are ready to make bold changes, then be sure to adopt the practices below, and in no time your company will blend right in with a sizable

Last month an article in New Scientist crossed my desk.  The title was “Non-Consenting Adults,” so I expected a thoughtful, balanced piece on the nuances of informed consent and the difficulties of ensuring that research volunteers know what they are signing up for. Imagine my surprise when the subheadline and introductory paragraph subtly implied that